Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722041 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket
ElectronicAdd to Basket



Advances in Coronary Angioplasty: Drug Eluting Stents
Datamonitor, Oct 2001


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

The development of drug-eluting stents has emerged since the use of stenting became particularly prevalent, especially in the US. Stents are currently used in approximately 70%-90% of cardiovascular interventional procedures and have been shown to reduce the need for repeat percutaneous transluminal coronary angioplasty (Ptca) due to restenosis. There are, however, issues of in-stent thrombosis and in-stent restenosis that need to be addressed when analyzing the results of clinical trial data. Over the next few years, additional long-term studies will aim to provide details of the long-term outcome for drug-eluting stents. In light of recent advances in this field of research, this brief sets out to: *describe the stenting procedure and outline the overall use of stents in coronary interventional procedures *outline recent advances in procedures, such as brachytherapy and sonotherapy, and establish the main advantages and disadvantages of each type of intervention *analyze clinical trial data and company strategies for key drug-eluting stent programs, including in-depth review of sirolimus-eluting, paclitaxel-eluting and actinomycin D-eluting stent trials *compare drug-eluting stent developments against established interventions in order to determine the potential success and patient population for drug-eluting stents *provide a forecasted market size for the drug-eluting stent market to 2005, along with an identification of the key factors influencing the market during this period * analyze the potential impact of drug-eluting stents on pharmaceutical companies, in terms of the affect on the use of anti-thrombotic and anti restenotic agents.


Customers who bought this item also bought

Drug-Eluting Stents - Global Strategic Business Report

Drug Eluting Stents – Technology & Market Forecast

Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse Events With Drug-Eluting Stents Demand A New Safety Standard

Europe Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth

U.S. Market for Drug-Eluting & Bare Metal Stents 2009

Drug Eluting Stent (DES) Clinical Trial Analysis

US Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth

Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks?

Drug Eluting Stents Market - Current Situation & Future Forecast

Drug-Eluting Stents - Global Market Opportunities

Coronary Stents - Global Strategic Business Report

Coronary Stents - Global Market Trends



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds